Coronavirus pandemic has pushed many countries across the globe to develop vaccines that would stop the increasing number of infected cases. According to South China Morning Post's latest report, the COVID-19 vaccine developed by Chinese scientists is already in phase two of the trial. They claimed that the trial showed significant neutralizing antibody responses for hundreds of volunteers.
5,000 Volunteers Sign up for Coronavirus Vaccine Trial in China's Wuhan City - News18 #politics https://t.co/0CuoI74uvO pic.twitter.com/iMeVUf8Afh — Sachin Kumar (@sac_isin) March 29, 2020
129 individuals participated in the vaccine trial. 72% of the patients received the medium dose, while 74% received the lower dose. One patient showed a negative reaction with the vaccine, but none of them developed serious adverse reactions.
On the other hand, Oxford's vaccine also showed promising results, which were also published by The Lancet. The vaccine produced by the Cambridge-based pharmaceutical company AstraZeneca was injected to 543 participants.The experimental coronavirus vaccine developed both humoral and cellular responses against Sars-CoV-2. The antibodies were produced 28 days after the vaccine was injected, remaining high for up to 2 months.
